Ultralife Corp (ULBI)
NASDAQIndustrialsElectrical Equipment & PartsSnapshot 2026-09-04
$6.13+0.49%
Close 2026-09-04 · 1-day change
NASDAQIndustrialsElectrical Equipment & PartsSnapshot 2026-09-04
Warn: Primary pillar under pressure — Achieve revenue growth near $225 million: Q2 rev $47.9M, YoY -1.3% vs FY26 target $224.9M.
Ultralife aims to restore profitability and generate cash flow. Analysts expect revenue near $225 million and EPS of $0.93 in 2026. The company invests in new products and strategic capital spending. Its stock trades cheaply compared to peers.
Ultralife has missed earnings repeatedly and remains loss-making. Net income was negative $451,000 in Q1 2026. The company faces elevated risk and sector headwinds. Revenue growth and profitability may not materialize as hoped.
The stock price is about 59% below our valuation level. Analysts expect roughly 15% revenue growth in the next year. The market reflects significant uncertainty and risk given recent losses and earnings misses.
Breaks if: significant reduction in capital expenditures
Maintain capital discipline to support strategic capital expenditures aligned with growth and operational improvement plans in 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the industrial sector. The current thesis state is cautious, as recent performance has not met expectations, and the company is facing elevated risks.
The market currently prices ULBI as cheap compared to its peers, with a low expectations gap. However, there is a risk that the stock could react negatively if guidance is cut or if sector leaders start to miss earnings.
Management is focused on restoring profitability and generating cash flow, with some success in recent quarters. However, there is an elevated risk of missing earnings in the near term, as the company has a history of recent misses.
The thesis hinges on the performance of sector bellwethers like ETN, VRT, and BE. If these companies continue to perform well, it could provide a tailwind for ULBI. Conversely, any negative guidance from these leaders could further pressure ULBI's performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Long-term debt declined from $44.2M in 2026-Q1 to $42.9M in 2026-Q2, indicating some progress in debt reduction. Management continues to emphasize supporting strategic capital expenditures funded by incremental cash flow, showing delivering trajectory.
“These improvements... position Ultralife to reduce debt, support strategic capital expenditures, continue our investment in new product development...”
“These improvements... position Ultralife to reduce debt, support strategic capital expenditures, continue our investment in new product development...”
Breaks if: significant cuts to R&D investment
Continue investing in new product development to expand product offerings and support future growth opportunities.
Stated as a priority in 2 of last 2 quarters. R&D expenses increased from $2.3M in 2026-Q1 to $3.2M in 2026-Q2, reflecting continued investment in new product development. Management consistently highlights this investment as key to future growth, showing delivering trajectory.
“Operating expenses reflect an increase in new product development costs related to continued investment in our product offering.”
“Operating expenses reflect a 23.3% increase in new product development costs related to continued investment in our product offering.”
Breaks if: net income remains negative through FY26
Focus on improving manufacturing efficiencies, executing backlog, and driving profitable growth to restore profitability and generate incremental cash flow in 2026.
Stated as a priority in 2 of last 2 quarters. Revenue was stable at $47.4M in 2026-Q1 and $47.9M in 2026-Q2. Net income improved from a loss of $451K in 2026-Q1 to a profit of $2.54M in 2026-Q2. Management is delivering on restoring profitability and generating cash flow with improving operating income and backlog.
“These multi-year revenue opportunities combined with our ongoing gross margin improvement initiatives, reinforce our outlook for profitable growth in 2026.”
“These improvements, along with execution and replenishment of our backlog, position Ultralife to restore profitability and generate incremental cash flow for 2026.”
Breaks if: revenue falls below $200 million in FY26
In the next 1 to 3 years, ULBI's outlook will depend heavily on sector dynamics and management's ability to execute on their priorities. Not investment advice.